Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Dasatinib; Dexamethasone
- Indications Acute lymphoblastic leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 29 Mar 2017 Planned number of patients changed from 30 to 12.
- 06 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.